Local Anesthesia Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Local Anesthesia Drugs Market is segmented by Drug Type (Bupivacaine, Lidocaine, Benzocaine, Ropivacaine, Prilocaine, Chloroprocaine, and Others), Mode of Administration (Injectable and Surface Anesthetic) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.91 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global local anesthesia drugs market was valued at USD 2,526.86 million in 2020, and it is expected to reach USD 3,378.43 million by 2026, registering a CAGR of 4.91% during the forecast period.

The use of local anesthesia in treating patients infected with COVID-19 is in high demand due to its benefits and minimal risk of viral transmission. Additionally, the research article published in the European Archives of Oto-Rhino-Laryngology in 2020 revealed that the topical oropharyngeal lignocaine application significantly increased comfort levels for the patient during oropharyngeal sampling for COVID-19 and had no effect on the detection of SARS-CoV-2 in the upper airway. Thus, the study suggested that topical oropharyngeal lignocaine should be considered as a measure to reduce the viral inoculum sampling of a COVID-19 suspect.

The growth of the global local anesthesia drugs market is driven by various factors, such as the rising number of surgeries requiring local anesthesia, increasing product approvals, and the growing usage of local anesthetic for postoperative pain.

According to the United Nations World Ageing 2019 report, there were around 703 million people aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. Globally, the population aged 65 years or over increased from 6% in 1990 to 9% in 2019. The geriatric population is prone to chronic diseases that lead to organ function failures, as there are changes in the pharmacokinetics and pharmacodynamics related to age and organ function. This factor is expected to increase the number of surgeries, which will drive the growth of the studied market.

Furthermore, the development and approvals of novel local anesthesia drugs prove to be a new revenue-generating resource for the companies in the market. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line that specifically targets those with chronic pain and numbing of muscles externally.

Additionally, the increased funding for the research and development of novel drugs by the pharma companies is also expected to drive market growth. For instance, members of the Pharmaceutical Research and Manufacturers of America (PhRMA) invested USD 83 billion in R&D in 2019, establishing the biopharmaceutical sector as the most R&D-intensive industry in the US economy.

The growing research on local anesthetics is also boosting the market growth. Istituti Ospitalieri di Cremona, Italy, started a clinical trial in 2017, in order to compare the effectiveness of blind local anesthetic infiltration with ultrasound-guided transversals fascia block and spinal anesthesia in patients undergoing inguinal hernia repair surgery. The results of the research are yet to be published. However, the side effects of these drugs and strict regulatory framework are expected to restrain the market studied.

Scope of the Report

As per the scope of the report, local anesthetics restrict the transmission of nerve impulses from the targeted region to the spinal cord. Local anesthetics are much safer to use, and they have fewer side effects, as compared to general anesthetics. 

The Local Anesthesia Drugs Market is segmented by Drug Type (Bupivacaine, Lidocaine, Benzocaine, Ropivacaine, Prilocaine, Chloroprocaine, and Others), Mode of Administration (Injectable and Surface Anesthetic) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Drug Type
By Mode of Administration
Surface Anesthetic
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Bupivacaine is Expected to Register a Significant Growth in the Forecast Years

Bupivacaine is a prescription medication used as a local anesthetic that blocks the nerve impulses that send pain signals to the brain. This injection is a very useful anesthetic for local and regional anesthesia for several procedures, such as surgery and diagnostic, therapeutic, and obstetrical procedures. It is used in various surgical procedures.

Although all local anesthetics cause changes in the cardiac and central nervous system functions, in the case of Bupivacaine, when injected intravascularly into toxic blood concentrations, it can cause an atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in death.

Pacira Pharmaceuticals Inc. is one of the growing companies recognized for its drug Exparel globally. LGM Pharma, Pfizer, Sagent Pharmaceuticals Inc., and BOC Sciences are the key players globally. In March 2021, the US Food and Drug Administration (FDA) approved the submission of supplemental new drug application (sNDA) submitted by Pacira BioSciences Inc. for the expanded use of its Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients. However, Bupivacaine is widely used as local anesthesia due to its efficacy in numbing certain organs. Hence, the rising number of surgeries leads to the high demand for local anesthesia drugs, and it is expected to propel the growth of the market.

Local Anesthesia Drugs Market 1

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the local anesthesia drugs market and is expected to continue its stronghold in the market. The North American anesthesia market is the largest regional market in the world. The market is mainly driven by factors, such as the increasing number of surgeries, the rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.

For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, about 2,314,720 cosmetic surgical procedures were performed in the United States, as compared to 1,901,049 procedures in 2000. There has been a 22% increase in the adoption rate of these surgical procedures, within a decade. These statistics clearly indicate that surgical procedures are constantly increasing in the region.

As per the Canadian Institute for Health Information (CIHI), around 104,349 Caesarean section deliveries, 70,215 knee replacement surgeries, 55,294 fracture rectifications, 42,449 coronary artery angioplasties, and 58,333 hip replacement surgeries were performed in the country during 2017-2018. These statistics indicate that the demand for local anesthesia is expected to be high in the near future

In addition, several companies are focusing on new product launches and seeking product approvals in Canada. For instance, in December 2019, Heron Therapeutics Inc., a commercial-stage biotechnology company, was granted a review status and accepted by Health Canada for its new drug submission (NDS) for HTX-011, an investigational dual-acting, fixed-dose combination of the local anesthetic called Bupivacaine, along with a low dose of the nonsteroidal anti-inflammatory drug, Meloxicam, for the management of post-operative pain.


Competitive Landscape

The Local Anesthesia Drugs market is competitive and many of the global players are in the market. Companies are focusing on major collaborations, mergers, and acquisitions in order to enhance their market share. Market players are also focusing on R&D to improve product quality and minimize manufacturing costs, developing novel products to improve patient compliance and safety. 

Recent Development

In March 2021, Luye Pharma Group received approval for clinical trials by the Centre for Drug Evaluation of China’s National Medical Products Administration for its LY09606, the first Ropivacaine multivesicular liposome formulation local anesthetic to be used as a postoperative analgesic.

In December 2020, Hikma Pharmaceuticals PLC (UK), the multinational pharmaceutical company, launched Ropivacaine HCl Injection - USP 40mg/20m. Ropivacaine HCl Injection USP is used for the production of local or regional anesthesia for surgery and acute pain management.

Table of Contents


    1. 1.1 Study Assumptions and Market Definiton

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Surgeries

      2. 4.2.2 New Approval of Anesthetic Drugs

      3. 4.2.3 Growing Use of Local Anesthetic in Post-operative Pain

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Anesthetic Drugs

      2. 4.3.2 Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Bupivacaine

      2. 5.1.2 Lidocaine

      3. 5.1.3 Benzocaine

      4. 5.1.4 Ropivacaine

      5. 5.1.5 Prilocaine

      6. 5.1.6 Chloroprocaine

      7. 5.1.7 Others

    2. 5.2 By Mode of Administration

      1. 5.2.1 Injectable

      2. 5.2.2 Surface Anesthetic

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Baxter International Inc.

      2. 6.1.2 Fresenius SE & Co. KGaA

      3. 6.1.3 Glenmark Pharmaceutical Inc.

      4. 6.1.4 Mylan N.V.

      5. 6.1.5 Pacira Pharmaceuticals, Inc.

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Septodont

      8. 6.1.8 Teva Pharmaceutical Industries Ltd

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Local Anesthesia Drugs Market market is studied from 2018 - 2026.

The Global Local Anesthesia Drugs Market is growing at a CAGR of 4.91% over the next 5 years.

The Global Local Anesthesia Drugs Market is valued at 2526 Million USD in 2018.

The Global Local Anesthesia Drugs Market is valued at 3378 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Fresenius SE & Co. KGaA, Glenmark Pharmaceutical Inc., Pacira Pharmaceuticals, Inc., Pfizer Inc., Septodont are the major companies operating in Global Local Anesthesia Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!